After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...